People with Down syndrome face a high risk of developing Alzheimer’s disease, which is the leading cause of death in this population over the age of 35. In this episode, Morgane Boillot (Senior Editor) is joined by Professor Michael Rafii to explore the intersection of Down syndrome and Alzheimer’s disease. They discuss the latest research into disease pathology, biomarkers, and clinical trials, and examine the key challenges and future opportunities in understanding and treating Alzheimer’s...
All content for The Lancet Neurology in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
People with Down syndrome face a high risk of developing Alzheimer’s disease, which is the leading cause of death in this population over the age of 35. In this episode, Morgane Boillot (Senior Editor) is joined by Professor Michael Rafii to explore the intersection of Down syndrome and Alzheimer’s disease. They discuss the latest research into disease pathology, biomarkers, and clinical trials, and examine the key challenges and future opportunities in understanding and treating Alzheimer’s...
People with Down syndrome face a high risk of developing Alzheimer’s disease, which is the leading cause of death in this population over the age of 35. In this episode, Morgane Boillot (Senior Editor) is joined by Professor Michael Rafii to explore the intersection of Down syndrome and Alzheimer’s disease. They discuss the latest research into disease pathology, biomarkers, and clinical trials, and examine the key challenges and future opportunities in understanding and treating Alzheimer’s...
